Divestiture • Life Science

3i Private Equity Acquires Xellia Pharmaceuticals

On April 1, 2008, private equity firm 3i Private Equity acquired life science company Xellia Pharmaceuticals from Alpharma for 258M USD

Acquisition Context
  • This is 3i Private Equity’s 6th transaction in the Life Science sector.
  • This is 3i Private Equity’s 21st largest (disclosed) transaction.
  • This is 3i Private Equity’s 4th transaction in Denmark.
Investment Fate
  • Xellia Pharmaceuticals was sold to a consortium of financial buyers in 2013 for 700M USD.

Explore All 789 Divestiture Life Science Deals - Search the Database Free


M&A Deal Summary

Date April 1, 2008
Target Xellia Pharmaceuticals
Sector Life Science
Buyer(s) 3i Private Equity
Sellers(s) Alpharma
Deal Type Divestiture
Deal Value 258M USD

Target Company

Xellia Pharmaceuticals

Copenhagen, Denmark
Xellia Pharmaceuticals is a provider and developer of anti-infective drugs, active pharmaceutical ingredients (API), and final dosage presentation. Its clients include a range of national, multinational, and global pharmaceutical and generic companies. Xellia Pharmaceuticals was formed in 1994 and is based in Copenhagen, Denmark.
Explore More Deals

Browse All 215,156 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

3i Private Equity

London, United Kingdom

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 1945
PE ASSETS 21.0B GBP
Size Mega
Type Sector Agnostic
DESCRIPTION

3i Private Equity is the private equity arm of 3i Group, a publicly held, global investment firm focused on private equity and infrastructure investing. 3i Private Equity generally targets buyout and growth capital financings and looks for opportunities across Europe, North America, and Asia. The Firm's targeted transaction range is €100 to €500 million. Industries of interest include business services, healthcare, consumer, media, oil/gas & power, technology, and financial services. 3i Group was originally formed in 1945 and is based in London.


Deal Context for Buyer #
Overall 181 of 251
Sector: Life Science 6 of 7
Type: Divestiture 4 of 9
Country: Denmark 4 of 7
Year: 2008 7 of 17
Size (of disclosed) 21 of 64
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-04-01 LHI Technology

Bao An, China

LHI Technology is a medical cables manufacturer. It is a major supplier to the growing global medical assemblies market and the only Asia-based supplier to develop, manufacture and sell medical cable assemblies exclusively to medical device companies and OEMs internationally. LHI Technology was founded in 1999 and is based in Bao An, China.

Buy €72M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2008-04-02 Giochi Preziosi

Milano, Italy

Giochi Preziosi S.p.A. is market leader in the Italian traditional toy industry and the fourth largest operator in the world.

Sell €740M

Seller Profile 1

SELLER

Alpharma

Piscataway, New Jersey, United States

Category Company
Founded 1998
Sector Life Science
DESCRIPTION

Alpharma Inc. is a global specialty pharmaceutical compan. Alpharma is also internationally recognized as a leading provider of pharmaceutical products for poultry and livestock.


Deal Context for Seller #
Overall 1 of 1
Sector: Life Science 1 of 1
Type: Divestiture 1 of 1
Country: Denmark 1 of 1
Year: 2008 1 of 1
Size (of disclosed) 1 of 1

Explore Related M&A Activity